137 related articles for article (PubMed ID: 31611440)
1. The role of p53, Ki-67 and laminin expression in the differential diagnosis of keratoacanthoma and well-differentiated SCC.
Turan G; Altun E; Aslan F; Kulahci O
Indian J Pathol Microbiol; 2019; 62(4):561-565. PubMed ID: 31611440
[TBL] [Abstract][Full Text] [Related]
2. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors.
Cain CT; Niemann TH; Argenyi ZB
Am J Dermatopathol; 1995 Aug; 17(4):324-31. PubMed ID: 8600793
[TBL] [Abstract][Full Text] [Related]
3. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
[TBL] [Abstract][Full Text] [Related]
4. Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma.
Lammoglia-Ordiales L; Toussaint-Caire S; Contreras-Barrera M; Fonte-Avalos V; Rodriguez-Carreón AA; Rivera-Macias S; Dominguez-Cherit J
J Drugs Dermatol; 2013 Mar; 12(3):e53-8. PubMed ID: 23545927
[TBL] [Abstract][Full Text] [Related]
5. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma.
Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
Br J Dermatol; 2001 Oct; 145(4):582-9. PubMed ID: 11703284
[TBL] [Abstract][Full Text] [Related]
6. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases.
Batinac T; Zamolo G; Jonjić N; Gruber F; Petrovecki M
Tumori; 2004; 90(1):120-7. PubMed ID: 15143984
[TBL] [Abstract][Full Text] [Related]
7. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
Kerschmann RL; McCalmont TH; LeBoit PE
Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
[TBL] [Abstract][Full Text] [Related]
8. Differential diagnosis of keratoacanthomas and squamous cell carcinomas: diagnostic value of DNA image cytometry and p53 expression.
Pilch H; Weiss J; Heubner C; Heine M
J Cutan Pathol; 1994 Dec; 21(6):507-13. PubMed ID: 7699117
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinoma arising in association with verruca vulgares and HPV-2: a clinicopathologic study with p16 and p53 immunohistochemical studies and human papillomavirus in situ hybridization studies.
Ruhoy SM; Guinee DG; Nuovo G
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):253-61. PubMed ID: 24717230
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma.
Batinac T; Zamolo G; Coklo M; Hadzisejdic I; Stemberger C; Zauhar G
Pathol Res Pract; 2006; 202(8):599-607. PubMed ID: 16781827
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p16, p53 and Ki-67 immunohistochemistry staining patterns can distinguish solitary keratoacanthoma from cutaneous squamous cell carcinoma.
Carr RA; Mesiano D; Heffron C; Radonic T; Wiggins J; Tso S; Agrawal R; Cheung E; Slater DN; Nichols L; Craig P
Pathology; 2023 Oct; 55(6):772-784. PubMed ID: 37573161
[TBL] [Abstract][Full Text] [Related]
13. Significance of Ki-67 and p53 immunoexpression in the differential diagnosis of oral necrotizing sialometaplasia and squamous cell carcinoma.
Dadfarnia T; Mohammed BS; Eltorky MA
Ann Diagn Pathol; 2012 Jun; 16(3):171-6. PubMed ID: 22197541
[TBL] [Abstract][Full Text] [Related]
14. The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study.
Bedir R; Güçer H; Şehitoğlu İ; Yurdakul C; Bağcı P; Üstüner P
Balkan Med J; 2016 Mar; 33(2):121-7. PubMed ID: 27403379
[TBL] [Abstract][Full Text] [Related]
15. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma.
Goldenhersh MA; Olsen TG
J Am Acad Dermatol; 1984 Feb; 10(2 Pt 2):372-8. PubMed ID: 6368620
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
Biesterfeld S; Josef J
Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
[TBL] [Abstract][Full Text] [Related]
17. Differences between keratoacanthoma and squamous cell carcinoma using TGF-alpha.
Cabrijan L; Lipozencić J; Batinac T; Lenković M; Zgombić ZS
Coll Antropol; 2013 Mar; 37(1):147-50. PubMed ID: 23697265
[TBL] [Abstract][Full Text] [Related]
18. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
Sakiz D; Turkmenoglu TT; Kabukcuoglu F
Pathol Res Pract; 2009; 205(9):589-94. PubMed ID: 19577853
[TBL] [Abstract][Full Text] [Related]
19. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Kaabipour E; Haupt HM; Stern JB; Kanetsky PA; Podolski VF; Martin AM
Arch Pathol Lab Med; 2006 Jan; 130(1):69-73. PubMed ID: 16390241
[TBL] [Abstract][Full Text] [Related]
20. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients.
Cabibi D; Aragona F; Guarnotta C; Rodolico V; Zerilli M; Belmonte B; Schillaci L; Aragona F
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):239-45. PubMed ID: 21475039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
